

AUTHORIZATION

No fee is required. The Commissioner is hereby authorized to charge any additional fees which may be required for this submission, or credit any overpayment to deposit account no. 50-0436.

Respectfully submitted,

PEPPER HAMILTON LLP

A handwritten signature in black ink, appearing to read 'R. Miller', followed by a long horizontal flourish.

Raymond A. Miller
Registration No. 42,981

Pepper Hamilton LLP
One Mellon Bank Center
50th Floor
500 Grant Street
Pittsburgh, PA 15219
Telephone: (412) 454-5813
Facsimile: (412) 281-0717
Date: April 13, 2007

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known			
				Application Number		10/769,218	
				Filing Date		January 30, 2004	
				First Named Inventor		Shi	
				Group Art Unit		1656	
Examiner Name		Alexander D. Kim					
Sheet	1	of	2	Attorney Docket Number		112911.01501	
U.S. PATENT DOCUMENTS							
Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number	Kind Code (if known)				
FOREIGN PATENT DOCUMENTS							
Examiner's Initials	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number				
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
Examiner's Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or county where published.					T
	CA	DEVERAUX, ET AL.; <i>IAP family proteins-suppressors of apoptosis</i> ; Genes Dev. 13: 239-252, 1999.					
	CB	KASOF, ET AL.; <i>Lim, a novel inhibitor of apoptosis protein family member</i> ; J Biol. Chem. 276: 3238-3246, 2001					
	CC	VUCIC DOMAGOJ, ET AL.; <i>ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanoma</i> ; Curr Biol. 10:1359-1366, 2000.					
	CD	ASHAB, YAOUB, et al. <i>Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution</i> ; Federation of European Biochemical Societies Letters 495:56-60, 2001					
	CE	DU, CHUNYING, ET AL.; <i>Smac, a Mitochondrial protein that promotes cytochrome c-dependent Caspase activation by eliminating IAP inhibition</i> ; Cell 102:33-42, 2000.					
	CF	VERHAGEN, ET AL.; <i>Identification of DIABLO, a mammalian protein that promotes Apoptosis by binding to and antagonizing IAP proteins</i> ; Cell 102:43-53, July 7, 2000.					
	CG	HAY, B A.; <i>Understanding IAP function and regulation: a view from Drosophila</i> ; Cell Death Differ. 7:1045-1056, 2000 (Abstract)					
	CH	BOXRUD, PAUL, D., ET AL.; <i>Streptokinase binds to human plasmin with high affinity, perturbs the plasmin active site, and induces expression of a substrate recognition exosite for plasminogen</i> ; J. Biol. Chem. 275: 14579-14589, 2000					
	CI	OWENIUS, RIKARD, ET AL.; <i>Properties of spin and fluorescent labels at a receptor-ligand interface</i> ; Biophys. J. 77:2237-2250, 1999.					
	CJ	HIRATSUKA, TOSHIKI, <i>ATP-induced opposite changes in the local environments around CYS³⁵⁷ (S112) and Cys³⁶⁷ (S111) of the myosin motor domain revealed by the pre-dan fluorescence</i> ; J. Biol. Chem. 274:29156-29163, 1999.					
	CK	CHIAN, W. C., WHITE, P. D.; <i>Fluor Solid Phase Peptide Synthesis: A Practical Approach</i> , Oxford University Press: Oxford 2000 (Table of Contents).					
	CL	FREIDINGER, ROGER, M., ET AL.; <i>Synthesis of 9-fluorenylmethoxycarbonyl-protected N-alkyl amino acids by reduction of oxazolidinones</i> ; J. Org. Chem. 48:77-81, 1983.					
	CM	SRINIVASA, et al.; <i>A conserved XIAP-interaction motif in Caspase-9 and Smac/DIABLO regulates Caspase activity and apoptosis</i> ; Nature., Vol 410 pp. 112-116; March 2001					
	CN	TIRWILLIGER, ET AL.; <i>Correlated Phasing of Multiple Isomorphous Replacement Data</i> ; Acta Cryst. (1996) D52, 749-757					
	CO	BAILEY, ET AL.; <i>The CCP4 Suite: Programs for protein crystallography</i> ; Acta Cryst. (1994) D50, 760-763					

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/769,218
				Filing Date	January 30, 2004
				First Named Inventor	Shi
				Group Art Unit	1656
				Examiner Name	Alexander D. Kim
Sheet	2	of	2	Attorney Docket Number	112911.01501
CP	SUN, ET AL.; <i>NMR Structure and Mutagenesis of the Third Bar Domain of the Inhibitor of Apoptosis Protein XIAP</i> ; <i>J of Biol. Chem.</i> Vol. 275, Issue of October 27, pp. 33777-33781, 2000				
CQ	RIPKA, et al.; <i>PEPTIDOMIMETIC DESIGN</i> ; <i>Chem. Biol.</i> 1998, 2:441-452, 1998				
CR	NICHOLLS, et al.; <i>Protein folding and association: Insights from the interfacial and thermodynamic properties of hydrocarbons</i> ; <i>Proteins: Structures, Functions and Genetics</i> 11:281-296 (1991)				
CS	NAVAZA, J.; <i>AmoRE: an automated package for molecular replacement</i> , <i>Acta Cryst.</i> (1994) A50, 157-163				
CT	MORGAN, ET AL.; Ch. 26, Section VI-Topics in Chemistry and Drug Design, "Approaches to the Discovery of Non-Peptide Receptors and Peptidases", Academic Press, Inc., 1989				
CU	MCARTHY, ET AL.; <i>Apoptosis induced by Drosophila Reaper and Grim in a Human System</i> ; <i>J. Biol. Chem.</i> ; Vol. 273, No. 37, September 11, 1998; pp. 24009-24015				
CV	LIU, ET AL.; <i>Structural basis for the binding of Smac/DIABLO to the XIAP BIR3 Domain</i> ; <i>Nature</i> Vol. 408 21/28 December 2000, pp. 1004-1008				
CW	LISI, ET AL.; <i>Diverse domains of XIAP/DIAP1 are required to inhibit apoptosis induced by REAPER and HID in drosophila</i> ; <i>Genetics</i> 154:669-678; February 2000				
CX	KRAULIS, J.; <i>Molscript, a program to produce both detailed and schematic plots of protein structures</i> ; <i>J. Appl. Cryst.</i> (1991) 24, 946-950				
CY	JONES, ET AL.; <i>Improved methods for building protein models in electron density maps and the location of errors in these models</i> ; <i>Acta. Cryst.</i> (1991) A47,110-119				
CZ	HRUBY, ET AL.; <i>Synthesis of oligopeptide and peptidomimetic libraries</i> ; <i>J. Chem. Biol.</i> 1997, 1:114-119; http://biomednet.com/elecref/1367583199199114				
CCA	HRUBY, ET AL.; <i>Conformational and topographical considerations in designing agonist Peptidomimetics from peptide leads</i> ; <i>Current Med. Chemistry</i> , 2000, 7, 945-970				
CCB	GOYAL, ET AL.; <i>Induction of Apoptosis by Drosophila Reaper, hid and grim through inhibition of IAP function</i> ; <i>EMBO Journal</i> , Vol. 19, No. 4, pp. 589-587, 2000				
CCC	DU, ET AL.; <i>Smac, a mitochondrial protein that promotes cytochrome c-Dependent Caspase activation by eliminating IAP inhibition</i> ; <i>Cell</i> , Vol. 102, 33-42, July 7, 2000				
CCD	CHEN, PO, ET AL.; <i>Grim, a novel cell death gene in Drosophila</i> ; <i>Genes & Development</i> 10:1773-1782 (1996)				
CCE	AMBROSINI, GRAZIA, ET AL.; <i>Induction of Apoptosis and Inhibition of Cell Proliferation by surviving gene targeting</i> ; <i>J of Biological Chemistry</i> , Vol. 273, No. 18, May 1, 1998; pp. 11177-11182				
CCF	YUIC, DOMAGÖL, ET AL.; <i>Inhibition of Reaper-induced apoptosis by interaction with inhibitor of apoptosis proteins (IAP)</i> ; <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 94, pp. 10188, September 1997				
CCG	CHAI, JULIE, ET AL.; <i>Structural and Biochemical basis of apoptotic activation by Smac/DIABLO</i> ; <i>Nature</i> ; Vol. 406, pp. 85862, August 2000				
CCH	SRINIVASA, M. SRINIVASULA, ET AL.; <i>Molecular Determinants of the Caspase-promoting activity of Smac/DIABLO and its role in the death receptor pathway</i> ; <i>J.Biological Chem.</i> , V. 275, No. 46, Nov. 17, 2000, pp. 36152-36157				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.